Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Jimenez

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
European Journal of Haematology|June 15, 2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in CanadaDonna E Reece, Esther Masih-Khan, Ehetu G Atenafu, et al.
Ejhaem|June 19, 2024
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) databaseRayan Kaedbey, Donna Reece, Christopher P Venner, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2026
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES TrialsAshutosh D Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, et al.
Ejhaem|December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
Ligand diversity contributes to the full activation of the jasmonate pathway in <i>Marchantia polymorpha</i>Sophie Kneeshaw, Gonzalo Soriano, Isabel Monte, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) AnalysisArleigh McCurdy, Engin Gul, Donna Reece, et al.
Blood Neoplasia|May 25, 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian reportMartha L Louzada, Donna Reece, Christopher P Venner, et al.
Transplantation and Cellular Therapy|July 6, 2024
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group DatabaseChristopher P Venner, Peter Duggan, Kevin Song, et al.
Blood Advances|March 10, 2019
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical modelChandini M Thirukkumaran, Zhong Qiao Shi, Gerard J Nuovo, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
European Journal of Haematology|June 15, 2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in CanadaDonna E Reece, Esther Masih-Khan, Ehetu G Atenafu, et al.
Ejhaem|June 19, 2024
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) databaseRayan Kaedbey, Donna Reece, Christopher P Venner, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2026
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES TrialsAshutosh D Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, et al.
Ejhaem|December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
Ligand diversity contributes to the full activation of the jasmonate pathway in <i>Marchantia polymorpha</i>Sophie Kneeshaw, Gonzalo Soriano, Isabel Monte, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) AnalysisArleigh McCurdy, Engin Gul, Donna Reece, et al.
Blood Neoplasia|May 25, 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian reportMartha L Louzada, Donna Reece, Christopher P Venner, et al.
Transplantation and Cellular Therapy|July 6, 2024
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group DatabaseChristopher P Venner, Peter Duggan, Kevin Song, et al.
Blood Advances|March 10, 2019
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical modelChandini M Thirukkumaran, Zhong Qiao Shi, Gerard J Nuovo, et al.
Pageof 16